Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aspirin inhibits the enzyme cyclooxygenase (Cox), and there is a significant body of epidemiological evidence demonstrating that regular aspirin use is associated with a decreased incidence of developing cancer. Interest focussed on selective Cox-2 inhibitors both as cancer prevention agents and as therapeutic agents in patients with proven malignancy until concerns were raised about their toxicity profile. Aspirin has several additional mechanisms of action that may contribute to its anti-cancer effect. It also influences cellular processes such as apoptosis and angiogenesis that are crucial for the development and growth of malignancies. Evidence suggests that these effects can occur through Cox-independent pathways questioning the rationale of focussing on Cox-2 inhibition alone as an anti-cancer strategy. Randomised studies with aspirin primarily designed to prevent cardiovascular disease have demonstrated a reduction in cancer deaths with long-term follow-up. Concerns about toxicity, particularly serious haemorrhage, have limited the use of aspirin as a cancer prevention agent, but recent epidemiological evidence demonstrating regular aspirin use after a diagnosis of cancer improves outcomes suggests that it may have a role in the adjuvant setting where the risk:benefit ratio will be different.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 1×
“…included seven randomised trials of aspirin for primary or secondary prevention of vascular disease (Table 1) with an average treatment period of at least 4 years (Rothwell et al, 2011) showed a reduction in deaths from all cancers after 5 years of follow-up (HR 0.66, 95% CI: 0.50–0.87, P¼ 0.003).”
BackgroundInfluentialRothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 3×
“…whose tumours overexpressed Cox-2, and that those who had taken aspirin before diagnosis did not appear to benefit from taking aspirin adjuvantly (Rothwell et al, 2010) gives an indication as to who may benefit from aspirin after a cancer diagnosis and emphasises the need for pathological…”
BackgroundMethodResultInfluentialFlossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796 · cited 2×
“…trials designed to evaluate low-dose aspirin (100 or 325 mg on alternate days) as a primary prevention strategy against cancer, with a mean follow-up of B10 years, did not show a reduction in the risk of developing colorectal cancer (Sturmer et al, 1998; Cook et al, 2005) (Table 1 and Figure 2A).”
BackgroundLANGENBACH, R., LOFTIN, C. D., LEE, C., & TIANO, H. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08723.x · Cited by 170
Cited by
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
“Headaches 20 (67) 18 (60) Coughing 5 (17) 5 (17) Sore throat 4 (13) 6 (20) Insomnia 5 (17) 4 (13) Diarrhea 3 (10) 6 (20) Upper respiratory infection 4 (13) 2 (7) Nasal congestion 4 (13) 2 (7) Myalgia 4 (13) 1 (3) Panic attacks 2 (7) 3 (10) Rash 4 (13) 1 (3) Fever 1 (3) 1 (3) Increased presence of urinary leukocyte est…”
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Self-citationCook, N. R., Lee, I.-M., Zhang, S. M., Moorthy, M. V., & Buring, J. E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00002 · Cited by 315
Aspirin and cancer risk: a quantitative review to 2011
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J., & La Vecchia, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds113 · Cited by 297
Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
Pantziarka, P. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.485 · Cited by 280
Metadata
- Authors
- Langley, R. E., Burdett, S., Tierney, J. F., Cafferty, F., Parmar, M. K. B., & Venning, G.
- Venue
- British Journal of Cancer
- Published
- 2011-08-16
- Volume
- 105
- Issue
- 8
- Pages
- 1107-1113
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2145857851
- Cited by
- 144
- References
- 6
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? https://app.cochat.ai/papers/10.1038/bjc.2011.289
- The paper
- Langley, R. E., Burdett, S., Tierney, J. F., Cafferty, F., Parmar, M. K. B., & Venning, G. (2011). Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? British Journal of Cancer. https://doi.org/10.1038/bjc.2011.289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.